RESUMEN
Optimal combination of chlorhexidine bigluconate with ascorbic acid, succinic acid, and zinc oxide was found as a result of comparative trials. The composition shows antioxidative effects and is capable of initiating antibody producing and phagocytosis. This combination can be used as an active substance of orodispersible tablets for the treatment respiratory tract infections.
Asunto(s)
Antibacterianos/farmacología , Antioxidantes/farmacología , Ácido Ascórbico/farmacología , Clorhexidina/análogos & derivados , Exudados y Transudados/efectos de los fármacos , Factores Inmunológicos/farmacología , Ácido Succínico/farmacología , Óxido de Zinc/farmacología , Administración Oral , Animales , Antibacterianos/uso terapéutico , Formación de Anticuerpos , Antioxidantes/uso terapéutico , Ácido Ascórbico/química , Ácido Ascórbico/uso terapéutico , Clorhexidina/química , Clorhexidina/farmacología , Clorhexidina/uso terapéutico , Combinación de Medicamentos , Escherichia coli/efectos de los fármacos , Factores Inmunológicos/uso terapéutico , Masculino , Ratones , Ratones Endogámicos BALB C , Fagocitosis/efectos de los fármacos , Ratas , Staphylococcus aureus/efectos de los fármacos , Ácido Succínico/química , Ácido Succínico/uso terapéutico , Comprimidos , Óxido de Zinc/química , Óxido de Zinc/uso terapéuticoRESUMEN
Preclinical safety of reamberin, a preparation of succinic acid intended for the treatment of patients with shock conditions of different etiology, and remaxol a drug intended for the treatment of patients with liver dysfunction caused by acute intoxication was performed. Both medicines belong to the 5th class of practically non-toxic drugs. Their administration to experimental animals for 30 days did not cause toxic effects on the functional and morphological state of main systems and organs. Both medicines do not affect specific (humoral and cellular) and non-specific immune response and do not cause sensibilization, mutagenic, embryotoxic and teratogenic effects, and also do no alter parameters of reproductive functions of rats.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Meglumina/análogos & derivados , Succinatos/efectos adversos , Succinatos/farmacología , Animales , Perros , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Meglumina/efectos adversos , Meglumina/farmacología , Ratas , Choque/tratamiento farmacológicoRESUMEN
The effect of purines on the activation and aggregation of thrombocytes in rats and rabbits was studied by the method of small-angle light scattering. The EC50 values of ADP, inducing the activation and aggregation of thrombocytes, reflect the sequence of the agonist action on various receptors: P2X1, 20-40 nM; P2Y1, 90-110 nM; P2YADP, 120-240 nM. It was demonstrated that ADP behaves as partial agonist not only with respect to P2X1 receptors, but with respect to P2Y1 receptors as well. Thrombocytes activated by 20 nM ADP or 100-nM ATP pass into a refracter state in the absence of further stimulation. The reaction halftime is tau 1/2 = 6.0 +/- 0.2 min for the cells activated with ADP and tau 1/2 = 16.5 +/- 0.2 min for ADP.